Spectral AI reports Q3 research and development revenue of $3.8 million

Reuters
Nov 12
<a href="https://laohu8.com/S/MDAI">Spectral AI</a> reports Q3 research and development revenue of $3.8 million

Spectral AI, Inc. reported research and development revenue of $3.8 million for the third quarter ended September 30, 2025, compared to $8.2 million in the same period of 2024. Year-to-date research and development revenue was $15.6 million, down from $22.0 million for the prior year period. The company reported a gross profit of $1.6 million for the third quarter and $7.1 million for the first nine months of 2025. Cash on hand as of September 30, 2025, was $10.5 million, up from $3.7 million at the same date in 2024. During the quarter, Spectral AI continued progress toward its De Novo FDA submission and maintained focus on the commercialization of its AI-driven diagnostic device.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spectral Ai Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573619-en) on November 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10